Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Interim Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial
Allison H. Scotch(Mayo Clinic in Arizona), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Wunna Swe(Huddersfield Royal Infirmary), Gunnar Birgegård(Uppsala University Hospital), Robyn M. Scherber(Blueprint Medicines (United States)), Deepti Radia(St Thomas' Hospital), Constantine S. Tam(The Alfred Hospital), John Hudson(Macclesfield District General Hospital), Heidi Kosiorek(Mayo Clinic in Florida), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), David M. Ross(Flinders Medical Centre), Jonathan Cullis(Salisbury University), Mohan Mahalakshmi(Colchester Hospital), Peter Johansson(Linköping University), Björn Andréasson(NU Hospital Group), Frances Wadelin(University of Nottingham), Federico Sackmann(Centre Hospitalier Universitaire de Grenoble), Paul Moreton(Pinderfields Hospital), Holly L. Geyer(Mayo Clinic Hospital), Jan Michiels(VIB-KU Leuven Center for Microbiology), Nigel Sargant(Basingstoke and North Hampshire Hospital), Victoria Drew(Bradford Royal Infirmary), Daniel M. Jennings(Royal Surrey County Hospital), Mallika Sekhar(Royal Free London NHS Foundation Trust), Mary Frances McMullin(Queen's University Belfast), Robert Lown(Anthony Nolan), Catherine Cargo(St James's University Hospital), Christen Lykkegaard Andersen(Copenhagen University Hospital), Satareh Shekouhi(Guy's Hospital), Amylou C. Dueck(Mayo Clinic in Arizona), Nan Zhang, Joanne Ewing(Heart of England NHS Foundation Trust), Jean‐Loup Demory(Centre Hospitalier Universitaire de Lille), Veena Fauble(Mayo Clinic in Arizona), Mari Kilner(Northumbria Healthcare NHS Foundation Trust), Ana Kerguelen Fuentes(Centre Hospitalier Universitaire de Grenoble), Elisabeth Ejerblad(Uppsala University)
Cited by 0
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
|JAMA|2017|2.3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k